- Advertise
- Contact Us
- Editorial Info
- Terms and Conditions
- Privacy Policy
- Do Not Sell My Personal Information
© 2021 MJH Life Sciences™ and Practical Cardiology. All rights reserved.
Antithrombotic Therapy
The Practical Cardiology™ Antithrombotic Therapy clinical resource center offers updates and information about the latest in the fields of antiplatelet and anticoagulation therapy. On this page you will find content related to FDA approvals and the latest information for preventing thrombosis in the form of articles, video interviews with leading experts, clinician-authored columns, and more.
Addition of Low-Dose Rivaroxaban to Algorithms Could Provide Benefit in CAD/PAD
July 10, 2021
An analysis of data from the COMPASS study suggests the addition of low-dose rivaroxaban to aspirin resulted in benefits, irrespective of concomitant therapies or comorbidities.
Dabigatran Etexilate (Pradaxa) Becomes First Oral Blood-Thinning Option for Use In Pediatric Patients
June 21, 2021
The FDA has granted approval to dabigatran etexilate (Pradaxa) for treatment of blood clots in pediatric patients with VTE and prevention of recurrent blood clots in those who have completed treatment for VTE.
Dissonance Between Clinicians and Patients Could Prevent Optimal Prescription of Oral Anticoagulants
May 19, 2021
An analysis of patient and clinician responses to surveys within BOAT-AF suggests many were willing to consider DOACs but were never prescribed anticoagulation and also provides insight into how trends in this cohort compared to those in the ACC's PINNACLE registry.
DAPT De-Escalation 30 Days After PCI Could Reduce Ischemic, Bleeding Events
May 16, 2021
The TALOS AMI study suggests DAPT de-escalation 30 days after PCI was associated with lower rates of bleeding and the study's composite endpoint of cardiovascular death, MI, or stroke.
ADAPTABLE Study Finds Optimal Aspirin Dose Could Come Down to Patient Preference
May 15, 2021
The ADAPTABLE study from DCRI suggests patients with existing CVD saw similar outcomes whether they were receiving 81 mg or 325 mg aspirin, but also suggests patients with the higher dose were more likely to discontinue therapy.
AHA/ASA Release Guidance for Treatment of COVID-19 Vaccine-Related Clotting, Low Platelet Counts
May 03, 2021
The American Heart Association and American Stroke Association have released a special report related to the treatment of blood clots or low platelet counts related to the COVID-19 vaccine, which has garnered mass amounts of attention despite being a rare complication.
Extended-Duration DAPT Reduces Mortality, Event Rate in TWILIGHT-like Patients
April 29, 2021
An SCAI 2021 analysis of more than 4k patients with characteristics similar to those included in the TWILIGHT trial indicates extended-duration DAPT, defined as a duration of more than 12 months post-PCI, was a more efficacious approach than short-term DAPT in this patient population.
A Hidden Hypothesis—Blood Clots and Myocardial Infarction with Arnold Meshkov, MD
March 23, 2021
In this column, Arnold Meshkov, MD, explores the history of the "Thrombus Hypothesis" and his experiences with thrombus in myocardial infarction as a practicing clinician.
Rivaroxaban Noninferior to Warfarin in AFib Patients w/ Bioprosthetic Mitral Valves
November 15, 2020
Results of the RIVER trial suggest rivaroxaban was noninferior to warfarin for the study's composite endpoint of all-cause mortality, major cardiovascular events, and major bleeding.
CAC Scoring Helps Determine Net Benefit or Harm of Aspirin in Primary Prevention
October 28, 2020
An analysis of the Dallas Heart Study from UTSW details how use of CAC scoring can help determine what patients would stand to benefit from aspirin use for primary prevention.